^
    9ms
    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=61, Recruiting, Kind Pharmaceuticals LLC | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    AND019
    almost2years
    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=61, Recruiting, Kind Pharmaceuticals LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    AND019
    over2years
    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=61, Not yet recruiting, Kind Pharmaceuticals LLC | Initiation date: Mar 2022 --> Aug 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    AND019
    almost3years
    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=61, Not yet recruiting, Kind Pharmaceuticals LLC
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    AND019